Literature DB >> 7796434

Valve replacement for regurgitant lesions of the aortic or mitral valve in advanced left ventricular dysfunction.

R O Bonow1, D Nikas, J A Elefteriades.   

Abstract

Patients with aortic regurgitation and severe left ventricular dysfunction remain candidates for aortic valve replacement, as long as the risks of late left ventricular dysfunction and congestive heart failure have been fully discussed with the patient, the patient's family, and the referring physician. In contrast, patients with mitral regurgitation and severe systolic dysfunction are at considerable risk of more severe left ventricular dysfunction after operation, especially if mitral valve repair or chordal-sparing procedure cannot be performed. In patients who are candidates for such procedures that preserve the integrity of the subvalvular mitral apparatus, operation may be successful in selected patients despite moderate-to-severe depression of systolic function. Prognosis is guarded to poor in patients with regurgitant valvular lesions and advanced left ventricular dysfunction, and the emerging alternative treatments discussed in other articles in this Cardiology Clinics deserve consideration in these patients.

Entities:  

Mesh:

Year:  1995        PMID: 7796434

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  3 in total

1.  Valvular regurgitation and stenosis: when is surgery required?

Authors:  R Goel; P P Sengupta; F Mookadam; H P Chaliki; B K Khandheria; A J Tajik
Journal:  Heart Asia       Date:  2009-01-01

Review 2.  Nontransplant surgical options for congestive heart failure.

Authors:  J Ferrão de Oliveira; Manuel J Antunes
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

3.  Outcomes of Aortic Valve Replacement for Chronic Aortic Insufficiency: Analysis of the Society of Thoracic Surgeons Database.

Authors:  Christopher T Ryan; Ayman Almousa; Rodrigo Zea-Vera; Qianzi Zhang; Christopher I Amos; Joseph S Coselli; Todd K Rosengart; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2021-04-25       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.